Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 12/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.37 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.33 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.33 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.33 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.33 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL315609 | 0.92 | KDM1A (0.43) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| SCHEMBL315773 | 0.92 | GAA (0.39) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| SCHEMBL316500 | 0.84 | GAA (0.41) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| Hydrochloric Acid SCHEMBL314663 | 0.83 | GAA (0.40) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| SCHEMBL315719 | 0.80 | GAA (0.36) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| SCHEMBL2860313 | 0.80 | GAA (0.36) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| SCHEMBL2847385 | 0.76 | HTR7 (0.33) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| Iodide SCHEMBL315798 | 0.75 | HTR7 (0.33) | HTR7HTR2AHTR1AGAAMCOLN3 | |
| SCHEMBL315919 | 0.73 | MAOA (0.42) | MAOB | |
| SCHEMBL316150 | 0.73 | LMNA (0.42) | HTR7HTR2AHTR1AGAAMCOLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2015-09-24 | — | — | US | claimed |
| EP-1831159-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-01-20 | — | — | EP | claimed |
| CN-101119965-A | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (CH) | 2008-02-06 | — | — | CN | claimed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | claimed |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC | 2006-07-27 | — | — | US | claimed |
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2021-09-16 | — | — | US | disclosed |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2020-04-16 | — | — | US | disclosed |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2018-11-08 | — | — | US | disclosed |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9670151-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8889906-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ROCHE PALO ALTO LLC | 2012-04-12 | — | — | US | disclosed |
| US-8093424-B2 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1831159-B1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2010-01-20 | — | — | EP | disclosed |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| US-7312359-B2 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | ROCHE PALO ALTO LLC | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167255-A1 | 2-(5-Benzenesulfonyl-indan-1-yl)-ethylamine, used as selective serotonin receptor antagonists for treatment of nervous system and gastrointestinal disorders | HTR2A, HTR1A, HTR5A | HTR7 13/4885HTR2A 1/4885HTR1A 2/4885 |
| US-20180319743-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | CYP3A7, PARK7, IPO5 | HTR7 23/4885HTR2A 1595/4885HTR1A 787/4885 |
| US-20080293751-A1 | Tetralin and indane derivatives and uses thereof | INSRR, RIF1, TTR | HTR7 750/4885HTR2A 1395/4885HTR1A 1561/4885 |
| US-20120088837-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | HTR7 750/4885HTR2A 1395/4885HTR1A 1561/4885 |
| US-20210284606-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | HTR7 87/4885HTR2A 1692/4885HTR1A 884/4885 |
| US-20200115333-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | HTR7 87/4885HTR2A 1692/4885HTR1A 884/4885 |
| US-20150266817-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | INSRR, RIF1, TTR | HTR7 750/4885HTR2A 1395/4885HTR1A 1561/4885 |
| US-20170247321-A1 | TETRALIN AND INDANE DERIVATIVES AND USES THEREOF | ERLIN1, INSRR, PSEN1 | HTR7 87/4885HTR2A 1692/4885HTR1A 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.